澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ISLAND PHARMACEUTICALS LTD

0.440

+0.0102.33%

成交量：27.89萬

成交額：12.24萬

市值：1.30億

市盈率：-12.09

高：0.445

開：0.440

低：0.430

收：0.430

52周最高：0.630

52周最低：0.295

股本：2.95億

流通股本：1.11億

量比：1.56

換手率：0.25%

股息：- -

股息率：- -

每股收益(TTM):-0.036

每股收益(LYR):-0.036

淨資產收益率：-95.50%

總資產收益率：-60.12%

市淨率：9.64

市盈率(LYR):-12.09

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Island Pharmaceuticals Ltd：本財年未派發、建議或宣派股息

Island Pharmaceuticals攜手Pi Health Sciences，追加生產GMP級Galidesivir

Island Pharmaceuticals股票交易暫停等待非洲埃博拉臨床試驗中Galidesivir使用情況公告

Island Pharmaceuticals啓動Galidesivir GMP生產，以支持依據FDA動物規則路徑的關鍵馬爾堡病毒研究

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/ILA.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ILA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ILA.AU\",,,,,undefined,":{"symbol":"ILA.AU","market":"AU","secType":"STK","nameCN":"ISLAND PHARMACEUTICALS LTD","latestPrice":0.44,"timestamp":1789452720000,"preClose":0.43,"halted":0,"volume":278949,"delay":0,"changeRate":0.023255813953488393,"nameEN":"ISLAND PHARMACEUTICALS LTD","floatShares":110756995,"shares":294766682,"eps":-0.0364,"marketStatus":"未開盤","change":0.01,"latestTime":"09-15 16:12:00 AEST","open":0.44,"high":0.445,"low":0.43,"amount":122386,"amplitude":0.034884,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0364,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.43,"openAndCloseTimeList":[[1789430400000,1789452000000]],"volumeRatio":1.5646609183397526,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ILA.AU","preClose":0.43,"auctionPrice":0.44,"auctionVolume":2642,"auction":3,"marketStatus":"盘后竞价","timestamp":1789452001622}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ILA.AU\",,,,,undefined,":{"symbol":"ILA.AU","floatShares":110756995,"roa":"-60.12%","roe":"-95.50%","lyrEps":-0.0364,"volumeRatio":1.5646609183397526,"shares":294766682,"dividePrice":0,"high":0.445,"amplitude":0.034884,"preClose":0.43,"low":0.43,"week52Low":0.295,"pbRate":"9.64","psRate":"458.85","week52High":0.63,"institutionHeld":0,"latestPrice":0.44,"eps":-0.0364,"divideRate":0,"volume":278949,"delay":0,"ttmEps":-0.0364,"open":0.44,"prevYearClose":0.43,"prevWeekClose":0.435,"prevMonthClose":0.44,"prevQuarterClose":0.38,"fiveDayClose":0.44,"twentyDayClose":0.455,"sixtyDayClose":0.37,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ILA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ILA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ILA.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1144643847","title":"Island Pharmaceuticals Ltd：本財年未派發、建議或宣派股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1144643847","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144643847?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 13:06","pubTimestamp":1787720769,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals Ltd 披露，在当前财务期间，公司既未派发股息，也未建议或宣派任何股息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ILA.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126028723","title":"Island Pharmaceuticals攜手Pi Health Sciences，追加生產GMP級Galidesivir","url":"https://stock-news.laohu8.com/highlight/detail?id=1126028723","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126028723?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 06:58","pubTimestamp":1787266689,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals已正式委托Pi Health Sciences，开展GMP级Galidesivir的追加生产工作。这一举措标志着该公司在抗病毒药物研发与供应链布局上迈出了关键一步。此次合作不仅强化了产能储备，也为后续临床及潜在商业化需求奠定了更坚实的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ILA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152078707","title":"Island Pharmaceuticals股票交易暫停 等待非洲埃博拉臨床試驗中Galidesivir使用情況公告","url":"https://stock-news.laohu8.com/highlight/detail?id=1152078707","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152078707?lang=zh_tw&edition=fundamental","pubTime":"2026-07-03 10:25","pubTimestamp":1783045517,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals Ltd  的股票交易已临时暂停，公司即将发布关于其抗病毒药物Galidesivir在非洲进行的埃博拉病毒病临床试验中应用情况的重要公告。此次交易暂停，预示着公司可能将披露与Galidesivir临床试验进展相关的关键信息。Galidesivir是一种广谱抗病毒核苷类似物，此前已被研究用于治疗多种病毒性疾病。市场正密切关注其在非洲针对埃博拉这一致命病毒的实际疗效数据。公告的发布，预计将为投资者评估该药物的研发前景及其对Island Pharmaceuticals未来价值的影响提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ILA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155692598","title":"Island Pharmaceuticals啓動Galidesivir GMP生產，以支持依據FDA動物規則路徑的關鍵馬爾堡病毒研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1155692598","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155692598?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 07:05","pubTimestamp":1780527932,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals Ltd已启动抗病毒药物Galidesivir的GMP（良好生产规范）生产。此举旨在为一项关键的马尔堡病毒研究提供支持。该研究将依据美国食品药品监督管理局的“动物规则”路径进行。这一进展标志着公司在推进该候选药物治疗病毒性出血热方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ILA.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ILA.AU\",params:#limit:6,delay:true,,,undefined,":[]}}